CNR1 and metabolic syndrome: Unpublished activities that were noteworthy included CNR1 inhibition of losartan (AC50 = 1.2 nM) and glipizide (AC50 = 19 nM), which may contribute to their therapeutic effect in treating hypertension and metabolic syndrome (the CNR1 antagonist rimonabant is used in the management of obesity18).